Moreover, combining IDCs with targeted therapies—such as AXL, VEGF, or CD47 inhibitors—could help to remodel the tumor microenvironment, reduce stromal barriers, and improve intratumoral drug penetration. This evidence concerns the gene CD47 and neoplasm.